These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 29905953)
1. Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond. Grasso G Mass Spectrom Rev; 2019 Jan; 38(1):34-48. PubMed ID: 29905953 [TBL] [Abstract][Full Text] [Related]
2. Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Michno W; Blennow K; Zetterberg H; Brinkmalm G J Neurochem; 2021 Oct; 159(2):234-257. PubMed ID: 34245565 [TBL] [Abstract][Full Text] [Related]
3. Mass spectrometry analysis of the diversity of Aβ peptides: difficulties and future perspectives for AD biomarker discovery. Zakharova NV; Bugrova AE; Kononikhin AS; Indeykina MI; Popov IA; Nikolaev EN Expert Rev Proteomics; 2018 Oct; 15(10):773-775. PubMed ID: 30253669 [No Abstract] [Full Text] [Related]
4. The use of mass spectrometry to study amyloid-β peptides. Grasso G Mass Spectrom Rev; 2011; 30(3):347-65. PubMed ID: 21500241 [TBL] [Abstract][Full Text] [Related]
5. Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications. Bros P; Delatour V; Vialaret J; Lalere B; Barthelemy N; Gabelle A; Lehmann S; Hirtz C Clin Chem Lab Med; 2015 Sep; 53(10):1483-93. PubMed ID: 25719328 [TBL] [Abstract][Full Text] [Related]
6. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Golde TE; Eckman CB; Younkin SG Biochim Biophys Acta; 2000 Jul; 1502(1):172-87. PubMed ID: 10899442 [TBL] [Abstract][Full Text] [Related]
7. Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians. Asih PR; Chatterjee P; Verdile G; Gupta VB; Trengove RD; Martins RN Neurodegener Dis Manag; 2014; 4(5):363-78. PubMed ID: 25405650 [TBL] [Abstract][Full Text] [Related]
8. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Prvulovic D; Hampel H Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022 [TBL] [Abstract][Full Text] [Related]
9. Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids. Galozzi S; Marcus K; Barkovits K Expert Rev Proteomics; 2015 Aug; 12(4):343-54. PubMed ID: 26153725 [TBL] [Abstract][Full Text] [Related]
10. Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry. Carlred L; Michno W; Kaya I; Sjövall P; Syvänen S; Hanrieder J J Neurochem; 2016 Aug; 138(3):469-78. PubMed ID: 27115712 [TBL] [Abstract][Full Text] [Related]
13. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease. Savelieff MG; DeToma AS; Derrick JS; Lim MH Acc Chem Res; 2014 Aug; 47(8):2475-82. PubMed ID: 25080056 [TBL] [Abstract][Full Text] [Related]
14. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689 [TBL] [Abstract][Full Text] [Related]
15. Mirror Image of the Amyloid-β Species in Cerebrospinal Fluid and Cerebral Amyloid in Alzheimer's Disease. Catania M; Di Fede G; Tonoli E; Benussi L; Pasquali C; Giaccone G; Maderna E; Ghidoni R; Tagliavini F J Alzheimers Dis; 2015; 47(4):877-81. PubMed ID: 26401767 [TBL] [Abstract][Full Text] [Related]
16. Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. Iwatsubo T Neurobiol Aging; 1998; 19(2):161-3. PubMed ID: 9558155 [No Abstract] [Full Text] [Related]